These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 15497688)

  • 1. Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans.
    Kumar GN; Jayanti VK; Johnson MK; Uchic J; Thomas S; Lee RD; Grabowski BA; Sham HL; Kempf DJ; Denissen JF; Marsh KC; Sun E; Roberts SA
    Pharm Res; 2004 Sep; 21(9):1622-30. PubMed ID: 15497688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans.
    Denissen JF; Grabowski BA; Johnson MK; Buko AM; Kempf DJ; Thomas SB; Surber BW
    Drug Metab Dispos; 1997 Apr; 25(4):489-501. PubMed ID: 9107549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease.
    Sham HL; Kempf DJ; Molla A; Marsh KC; Kumar GN; Chen CM; Kati W; Stewart K; Lal R; Hsu A; Betebenner D; Korneyeva M; Vasavanonda S; McDonald E; Saldivar A; Wideburg N; Chen X; Niu P; Park C; Jayanti V; Grabowski B; Granneman GR; Sun E; Japour AJ; Leonard JM; Plattner JJ; Norbeck DW
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3218-24. PubMed ID: 9835517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavir.
    ter Heine R; Van Waterschoot RA; Keizer RJ; Beijnen JH; Schinkel AH; Huitema AD
    J Pharm Sci; 2011 Jun; 100(6):2508-15. PubMed ID: 21491455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients.
    Crommentuyn KM; Kappelhoff BS; Mulder JW; Mairuhu AT; van Gorp EC; Meenhorst PL; Huitema AD; Beijnen JH
    Br J Clin Pharmacol; 2005 Oct; 60(4):378-89. PubMed ID: 16187970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of once-daily lopinavir/ritonavir and the influence of dose modifications.
    la Porte CJ; Schippers EF; van der Ende ME; Koopmans PP; Blok WL; Kauffmann RH; Kroon FP; Burger DM
    AIDS; 2005 Jul; 19(10):1105-7. PubMed ID: 15958844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: Acknowledgement of human bioequivalency of matrix's lopinavir-ritonavir formulation to Kaletra, comment to article on Bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in a dog model, by Garren et al.
    Rackley RJ
    J Pharm Sci; 2010 Feb; 99(2):568-71; author reply 574. PubMed ID: 19746411
    [No Abstract]   [Full Text] [Related]  

  • 8. Water-soluble prodrugs of the human immunodeficiency virus protease inhibitors lopinavir and ritonavir.
    DeGoey DA; Grampovnik DJ; Flosi WJ; Marsh KC; Wang XC; Klein LL; McDaniel KF; Liu Y; Long MA; Kati WM; Molla A; Kempf DJ
    J Med Chem; 2009 May; 52(9):2964-70. PubMed ID: 19348416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
    Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
    Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to the comparison of generic ritonavir (Ritomune, Cipla) and lopinavir/ritonavir tablets (Lopimune, Cipla) and the Abbott brand (Norvir soft-gel capsules and Kaletra tablets).
    Chachad S; Gogtay J; Malhotra G; Purandare S
    J Pharm Sci; 2010 Feb; 99(2):572-3; author reply 574. PubMed ID: 19718766
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105.
    Mukai H; Sugimoto T; Ago M; Morino A
    Arzneimittelforschung; 1999 Nov; 49(11):881-90. PubMed ID: 10604039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
    Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants.
    Dingemanse J; van Giersbergen PL; Patat A; Nilsson PN
    Antivir Ther; 2010; 15(2):157-63. PubMed ID: 20386070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials.
    Hill A; van der Lugt J; Sawyer W; Boffito M
    AIDS; 2009 Nov; 23(17):2237-45. PubMed ID: 19809270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
    van der Lee M; Verweel G; de Groot R; Burger D
    Antivir Ther; 2006; 11(4):439-45. PubMed ID: 16856617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals.
    van der Lugt J; Lange J; Avihingsanon A; Ananworanich J; Sealoo S; Burger D; Gorowara M; Phanuphak P; Ruxrungtham K
    Antivir Ther; 2009; 14(7):1001-4. PubMed ID: 19918104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABT 378/r: a novel inhibitor of HIV-1 protease in haemodialysis.
    Izzedine H; Launay-Vacher V; Legrand M; Lieberherr D; Caumes E; Deray G
    AIDS; 2001 Mar; 15(5):662-4. PubMed ID: 11317012
    [No Abstract]   [Full Text] [Related]  

  • 18. Bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in a dog model.
    Garren KW; Rahim S; Marsh K; Morris JB
    J Pharm Sci; 2010 Feb; 99(2):626-31. PubMed ID: 19230020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
    Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
    HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABT-378: a second generation protease inhibitor.
    Highleyman L
    BETA; 1998 Oct; ():8, 55. PubMed ID: 11365998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.